

Editorial

Editorial on Neonatal Hepatitis

Raajitha B*

Department of Pharmacology, University of JNTU, Kakinada, Andhra Pradesh, India

INTRODUCTION

Neonatal hepatitis is inflammation of the liver that occurs only in early infancy, usually between one and two months after birth. About 20 percent of infants with neonatal hepatitis are infected by a virus that caused the inflammation before birth bytheir mother or shortly after birth.

An infant with neonatal hepatitis usually has jaundice (yellow eyes and skin), that appears at one to two months of age, is not gaining weight and growing normally and has an enlarged liverand spleen. The infant cannot absorb vitamins for proper growth and most neonates with HBV infection areasymptomatic but develop chronic, subclinical infection characterized by persistent HBsAg antigenemia and variably elevated transaminase activity. Many neonates born to women with acute hepatitis B during pregnancy are of low birth weight, regardless of whether they are infected.

Diagnosis

Diagnosis of neonatal HBV infection is byserologic testing, including measurement of HBsAg, HBeAg, antibody to hepatitis B e antigen and quantitation of HBV DNA in blood. Other initial tests include complete blood count with platelets, alanine aminotransferase and alpha-fetoprotein levels, and liver ultrasonography. In the 80 percent of the cases where there is novirus identified as the cause, a liver biopsy is performed, where asmall piece of the liver is taken out of the child with a needle and examined under a microscope

Treatment

Neonatal hepatitis has no specific treatment, and vitamin supplements are usually prescribed to improve the baby's condition. Fever is normally controlled with the help of paracetamol or acetaminophen. There is a disruption in the flowof bile from the liver of jaundiced infants and supplementation with fat-soluble vitamins might help promote adequate growth and development. Infant formulas that contain easily digestible fats may be prescribed for newborn hepatitis. Most types of hepatitis including idiopathic neonatal hepatitis tend to improve about six months. But, if the infection is being caused by Hepatitis B or C virus, it is likely to lead to cirrhosis which needsa liver transplant.

Prevention

Pregnant women should be tested for HBsAg during an early prenatalvisit. Failing that, they should be tested when admitted for delivery. Some women who are HBsAg-positive are treated with lamivudine or telbivudine during the 3rd trimester, which may prevent perinatal transmission of HBV.

Neonates whose mothers are HBsAg-positive should be given 1 dose of HBIG 0.5 mL IM within 12 hours of birth. Recombinant HBV vaccine should be given IM in a series of 3 doses, as is recommended for all infants in the US

Neonates whose mothers are known HBsAg-negative should receive their first dose of vaccine within 24 hours of birth if they are medicallystable and weigh ≥ 2 kg. For infants ≤ 2 kg, administer 1 dose at age 1 month or before hospital discharge.

Correspondence to: Raajitha, Department of Pharmacology, University of JNTU, Kakinada, Andhra Pradesh, India. E- mail: raajitha.nrt@gmail.com Received: March 05, 2021, Accepted: March 16, 2021, Published: March 25, 2021

Citation: Raajitha B (2021) Editorial on Neonatal Hepatitis. J Neonatal Biol. Vol: 10, Iss: 3

Copyright: © 2021 Raajitha B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.